Description

Leqembi, known by the generic name Lecanemab, is a monoclonal antibody used to treat Alzheimer’s disease. It targets and reduces amyloid beta plaques, which are believed to play a role in the cognitive decline associated with Alzheimer's. Classified as an amyloid beta-directed antibody, Leqembi is recommended for patients experiencing mild cognitive impairment or mild dementia stages of the disease.

Directions

Leqembi is administered as an intravenous (IV) infusion. For those beginning treatment, the standard dosage is 10 mg/kg once every two weeks. A healthcare provider will recommend an MRI before and throughout treatment to monitor for signs of amyloid related imaging abnormalities (ARIA). When preparing the infusion, healthcare workers typically mix Leqembi with saline solution in an infusion bag.

Ingredients

Leqembi’s active ingredient is Lecanemab-irmb. The medication consists of various inactive components that support the stability and delivery of Lecanemab-irmb to the body. These inactive ingredients include arginine hydrochloride, histidine, and water for injection.

Contraindications

Leqembi is contraindicated in people with a known hypersensitivity to Lecanemab or any of its components. An allergic reaction could be dangerous and requires immediate attention.

Cautions

• Before starting treatment with Leqembi, consult a healthcare provider about the following:
• Any allergies to medications.
• All health conditions.
• Any medications.
• Whether you’re pregnant or breastfeeding.
• Leqembi may cause amyloid related imaging abnormalities (ARIA), which are generally without symptoms but can sometimes lead to serious or even life-threatening events. This may include significant bleeding in the brain.
• If you have two copies of the ApoE e4 gene (homozygotes), you are at a higher risk of experiencing ARIA, both symptomatic and serious, compared to those with one or no copies. It is recommended to test for ApoE e4 status before starting Leqembi to understand your risk level.
• Monitoring for ARIA is particularly important during the first 14 weeks of treatment with Leqembi. People with two copies of the ApoE e4 gene face a higher risk of symptomatic ARIA. If symptoms of ARIA occur, seek immediate medical attention, including an MRI if appropriate.
• Infusion-related reactions may happen during treatment with Leqembi. If such reactions occur, the infusion rate may need to be slowed down or stopped and appropriate medical treatment provided. Pre-medication with antihistamines, non-steroidal anti-inflammatory drugs, or corticosteroids may be considered for the following doses.

Side Effects

Patients taking Leqembi may notice mild side effects. Common Leqembi side effects may include infusion-related reactions, such as fever, flu-like symptoms, nausea, vomiting, dizziness, and changes in heart rate.

Serious side effects may include swelling in areas of the brain, sometimes accompanied by small spots of bleeding on or within its surface, a condition known as ARIA. Allergic reactions are also possible, which could develop as hives, difficulty breathing, and swelling of the face, lips, tongue, or throat. Serious side effects like these are rare but often require immediate attention by healthcare professionals.

References:

1. Leqembi (Lecanemab) Product Monograph. Nutley, NJ: Eisai Inc; 2023.
2. Leqembi (Lecanemab) Drug Label Information. Nutley, NJ: Eisai Inc; 2023.

About Dr. Gerardo Sison (Page Author)

Dr. Sison graduated with honors from the University of Florida. He began his career in pharmacy counseling patients in a community setting and later served in hospitals and clinics. He has also worked in medication therapy management services. Read More....

Product Code : 14422